{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:25:45Z","timestamp":1791062745964,"version":"4.1.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>There is initial evidence suggesting that biomarker neurogranin (Ng) may distinguish Alzheimer\u2019s disease (AD) from other neurodegenerative diseases. Therefore, we assessed (a) the discriminant ability of cerebrospinal fluid (CSF) Ng levels to distinguish between AD and frontotemporal lobar degeneration (FTLD) pathology and between different stages within the same disease, (b) the relationship between Ng levels and cognitive performance in both AD and FTLD pathology, and (c) whether CSF Ng levels vary by apolipoprotein E (<jats:italic>APOE<\/jats:italic>) polymorphism in the AD continuum.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Participants with subjective cognitive decline (SCD) (<jats:italic>n<\/jats:italic>\u2009=\u200933), amnestic mild cognitive impairment (aMCI) due to AD (<jats:italic>n<\/jats:italic>\u2009=\u2009109), AD dementia (<jats:italic>n<\/jats:italic>\u2009=\u200967), MCI due to FTLD (<jats:italic>n<\/jats:italic>\u2009=\u200925), and FTLD dementia (<jats:italic>n<\/jats:italic>\u2009=\u200929) were recruited from the Czech Brain Aging Study. One-way analysis of covariance (ANCOVA) assessed Ng levels in diagnostic subgroups. Linear regressions evaluated the relationship between CSF Ng levels, memory scores, and <jats:italic>APOE<\/jats:italic> polymorphism.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Ng levels were higher in aMCI-AD patients compared to MCI-FTLD (F[1, 134]\u2009=\u200915.16, <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001), and in AD-dementia compared to FTLD-dementia (F[1, 96]\u2009=\u20094.60, <jats:italic>p<\/jats:italic>\u2009=\u2009.029). Additionally, Ng levels were higher in FTLD-dementia patients compared to MCI-FTLD (F[1, 54]=\u20094.35, <jats:italic>p<\/jats:italic>\u2009=\u2009.034), lower in SCD participants compared to aMCI-AD (F[1, 142]\u2009=\u200910.72, <jats:italic>p<\/jats:italic>\u2009=\u2009.001) and AD-dementia (F[1, 100]\u2009=\u200920.90, <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001), and did not differ between SCD participants and MCI-FTLD (F[1, 58]=\u20091.02, <jats:italic>p<\/jats:italic>\u2009=\u2009.491) or FTLD-dementia (F[1, 62]=\u20092.27, <jats:italic>p<\/jats:italic>\u2009=\u2009.051). The main effect of diagnosis across the diagnostic subgroups on A\u03b2<jats:sub>1\u221242<\/jats:sub>\/Ng ratio was significant too (F[4, 263]=, <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001). We found a non-significant association between Ng levels and memory scores overall (\u03b2=-0.25, <jats:italic>p<\/jats:italic>\u2009=\u2009.154) or in AD diagnostic subgroups, and non-significant differences in this association between overall AD <jats:italic>APOE<\/jats:italic> \u03b54 carriers and non-carriers (\u03b2=-0.32, <jats:italic>p<\/jats:italic>\u2009=\u2009.358).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this first study to-date to assess MCI and dementia due to AD or FTLD within one study, elevated CSF Ng appears to be an early biomarker of AD-related impairment, but its role as a biomarker appears to diminish after dementia diagnosis, whereby dementia-related underlying processes in AD and FTLD may begin to merge. The A\u03b2<jats:sub>1\u221242<\/jats:sub>\/Ng ratio discriminated AD from FTLD patients better than Ng alone. CSF Ng levels were not related to memory in AD or FTLD, suggesting that Ng may be a marker of the biological signs of disease state rather than cognitive deficits.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-024-01566-w","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T07:02:18Z","timestamp":1725606138000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["CSF neurogranin levels as a biomarker in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a cross-sectional analysis"],"prefix":"10.1186","volume":"16","author":[{"given":"Vanesa","family":"Jurasova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Andel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alzbeta","family":"Katonova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Veverova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terezie","family":"Zuntychova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Horakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Vyhnalek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"Kolarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaclav","family":"Matoska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Hort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,6]]},"reference":[{"key":"1566_CR1","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0025-7125(02)00010-X","volume":"86","author":"WA Kukull","year":"2002","unstructured":"Kukull WA, Bowen JD. Dementia epidemiology. Med Clin North Am. 2002;86:573\u201390.","journal-title":"Med Clin North Am"},{"key":"1566_CR2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","volume":"14","author":"MA DeTure","year":"2019","unstructured":"DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer\u2019s disease. Mol Neurodegener. 2019;14:32.","journal-title":"Mol Neurodegener"},{"key":"1566_CR3","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1136\/jnnp.2010.212225","volume":"82","author":"H Seelaar","year":"2011","unstructured":"Seelaar H, Rohrer JD, Pijnenburg YAL, Fox NC, van Swieten JC. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry. 2011;82:476\u201386.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1566_CR4","doi-asserted-by":"crossref","unstructured":"Antonioni A, Raho EM, Lopriore P, Pace AP, Latino RR, Assogna M et al. Frontotemporal Dementia, where do we stand? A narrative review. Int J Mol Sci. 2023;24.","DOI":"10.3390\/ijms241411732"},{"key":"1566_CR5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jalz.2012.03.002","volume":"9","author":"AL Boxer","year":"2013","unstructured":"Boxer AL, Gold M, Huey E, Gao F-B, Burton EA, Chow T, et al. Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development. Alzheimers Dement. 2013;9:176\u201388.","journal-title":"Alzheimers Dement"},{"key":"1566_CR6","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1523\/JNEUROSCI.10-12-03782.1990","volume":"10","author":"A Represa","year":"1990","unstructured":"Represa A, Deloulme JC, Sensenbrenner M, Ben-Ari Y, Baudier J. Neurogranin: immunocytochemical localization of a brain-specific protein kinase C substrate. J Neurosci. 1990;10:3782\u201392.","journal-title":"J Neurosci"},{"key":"1566_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13195-019-0564-2","volume":"11","author":"MTM Clarke","year":"2019","unstructured":"Clarke MTM, Brinkmalm A, Foiani MS, Woollacott IOC, Heller C, Heslegrave A, et al. CSF synaptic protein concentrations are raised in those with atypical Alzheimer\u2019s disease but not frontotemporal dementia. Alzheimers Res Ther. 2019;11:105.","journal-title":"Alzheimers Res Ther"},{"key":"1566_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/acn3.266","volume":"3","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Hertze J, Zetterberg H, Landqvist Wald\u00f6 M, Santillo A, Blennow K, et al. Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer\u2019s disease. Ann Clin Transl Neurol. 2016;3:12\u201320.","journal-title":"Ann Clin Transl Neurol"},{"key":"1566_CR9","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1212\/WNL.0000000000002423","volume":"86","author":"H Wellington","year":"2016","unstructured":"Wellington H, Paterson RW, Portelius E, T\u00f6rnqvist U, Magdalinou N, Fox NC, et al. Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology. 2016;86:829\u201335.","journal-title":"Neurology"},{"key":"1566_CR10","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00401-018-1851-x","volume":"136","author":"E Portelius","year":"2018","unstructured":"Portelius E, Olsson B, H\u00f6glund K, Cullen NC, Kvartsberg H, Andreasson U, et al. Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathol. 2018;136:363\u201376.","journal-title":"Acta Neuropathol"},{"key":"1566_CR11","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.jalz.2014.10.009","volume":"11","author":"H Kvartsberg","year":"2015","unstructured":"Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, \u00d6hrfelt A, Andersson K, et al. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer\u2019s disease. Alzheimers Dement. 2015;11:1180\u201390.","journal-title":"Alzheimers Dement"},{"key":"1566_CR12","doi-asserted-by":"crossref","unstructured":"Kulczy\u0144ska-Przybik A, Dulewicz M, Doroszkiewicz J, Borawska R, S\u0142owik A, Zetterberg H et al. The relationships between Cerebrospinal Fluid Glial (CXCL12, CX3CL, YKL-40) and synaptic biomarkers (Ng, NPTXR) in early Alzheimer\u2019s Disease. Int J Mol Sci. 2023;24.","DOI":"10.3390\/ijms241713166"},{"key":"1566_CR13","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1001\/jamaneurol.2015.1867","volume":"72","author":"MI Kester","year":"2015","unstructured":"Kester MI, Teunissen CE, Crimmins DL, Herries EM, Ladenson JH, Scheltens P, et al. Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer Disease. JAMA Neurol. 2015;72:1275\u201380.","journal-title":"JAMA Neurol"},{"key":"1566_CR14","doi-asserted-by":"crossref","unstructured":"Piccoli T, Blandino V, Maniscalco L, Matranga D, Graziano F, Guajana F et al. Biomarkers related to synaptic dysfunction to Discriminate Alzheimer\u2019s Disease from Other Neurological disorders. Int J Mol Sci. 2022;23.","DOI":"10.3390\/ijms231810831"},{"key":"1566_CR15","doi-asserted-by":"publisher","first-page":"11232","DOI":"10.1073\/pnas.210184697","volume":"97","author":"JH Pak","year":"2000","unstructured":"Pak JH, Huang FL, Li J, Balschun D, Reymann KG, Chiang C, et al. Involvement of neurogranin in the modulation of calcium\/calmodulin-dependent protein kinase II, synaptic plasticity, and spatial learning: a study with knockout mice. Proc Natl Acad Sci U S A. 2000;97:11232\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1566_CR16","doi-asserted-by":"publisher","first-page":"e887","DOI":"10.1212\/WNL.0000000000005057","volume":"90","author":"A Headley","year":"2018","unstructured":"Headley A, De Leon-Benedetti A, Dong C, Levin B, Loewenstein D, Camargo C, et al. Neurogranin as a predictor of memory and executive function decline in MCI patients. Neurology. 2018;90:e887\u201395.","journal-title":"Neurology"},{"key":"1566_CR17","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1093\/brain\/awaa395","volume":"144","author":"JB Pereira","year":"2021","unstructured":"Pereira JB, Janelidze S, Ossenkoppele R, Kvartsberg H, Brinkmalm A, Mattsson-Carlgren N, et al. Untangling the association of amyloid-\u03b2 and tau with synaptic and axonal loss in Alzheimer\u2019s disease. Brain. 2021;144:310\u201324.","journal-title":"Brain"},{"key":"1566_CR18","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1212\/WNL.0000000000004569","volume":"89","author":"KB Casaletto","year":"2017","unstructured":"Casaletto KB, Elahi FM, Bettcher BM, Neuhaus J, Bendlin BB, Asthana S, et al. Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers. Neurology. 2017;89:1782\u20138.","journal-title":"Neurology"},{"key":"1566_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1385\/JMN:23:3:167","volume":"23","author":"B Teter","year":"2004","unstructured":"Teter B. ApoE-dependent plasticity in Alzheimer\u2019s disease. J Mol Neurosci. 2004;23:167\u201379.","journal-title":"J Mol Neurosci"},{"key":"1566_CR20","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1073\/pnas.050004797","volume":"97","author":"DM Holtzman","year":"2000","unstructured":"Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer\u2019s disease. Proc Natl Acad Sci U S A. 2000;97:2892\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1566_CR21","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.neuint.2006.05.004","volume":"49","author":"RK Tannenberg","year":"2006","unstructured":"Tannenberg RK, Scott HL, Tannenberg AEG, Dodd PR. Selective loss of synaptic proteins in Alzheimer\u2019s disease: evidence for an increased severity with APOE varepsilon4. Neurochem Int. 2006;49:631\u20139.","journal-title":"Neurochem Int"},{"key":"1566_CR22","doi-asserted-by":"publisher","first-page":"39944","DOI":"10.1074\/jbc.M205147200","volume":"277","author":"EJ Weeber","year":"2002","unstructured":"Weeber EJ, Beffert U, Jones C, Christian JM, Forster E, Sweatt JD, et al. Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning. J Biol Chem. 2002;277:39944\u201352.","journal-title":"J Biol Chem"},{"key":"1566_CR23","doi-asserted-by":"publisher","first-page":"15317","DOI":"10.1523\/JNEUROSCI.4026-09.2009","volume":"29","author":"SB Dumanis","year":"2009","unstructured":"Dumanis SB, Tesoriero JA, Babus LW, Nguyen MT, Trotter JH, Ladu MJ, et al. ApoE4 decreases spine density and dendritic complexity in cortical neurons in vivo. J Neurosci. 2009;29:15317\u201322.","journal-title":"J Neurosci"},{"key":"1566_CR24","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.neurobiolaging.2021.02.008","volume":"102","author":"OH Butt","year":"2021","unstructured":"Butt OH, Long JM, Henson RL, Herries E, Sutphen CL, Fagan AM, et al. Cognitively normal APOE \u03b54 carriers have specific elevation of CSF SNAP-25. Neurobiol Aging. 2021;102:64\u201372.","journal-title":"Neurobiol Aging"},{"key":"1566_CR25","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40520-018-0948-3","volume":"31","author":"L Wang","year":"2019","unstructured":"Wang L, Alzheimer\u2019s Disease Neuroimaging Initiative. Association of cerebrospinal fluid neurogranin with Alzheimer\u2019s disease. Aging Clin Exp Res. 2019;31:185\u201391.","journal-title":"Aging Clin Exp Res"},{"key":"1566_CR26","doi-asserted-by":"publisher","first-page":"e030379","DOI":"10.1136\/bmjopen-2019-030379","volume":"9","author":"K Sheardova","year":"2019","unstructured":"Sheardova K, Vyhnalek M, Nedelska Z, Laczo J, Andel R, Marciniak R, et al. Czech Brain Aging Study (CBAS): prospective multicentre cohort study on risk and protective factors for dementia in the Czech Republic. BMJ Open. 2019;9:e030379.","journal-title":"BMJ Open"},{"key":"1566_CR27","first-page":"30","volume":"70","author":"J Hort","year":"2007","unstructured":"Hort J, Glosova L, Vyhnalek M, Bojar M, Skoda D, Hladikova M. The liquor tau protein and beta amyloid in Alzheimer\u2019s disease. \u010cesk\u00e1 Slovensk\u00e1 Neurologie Neurochirurgie. 2007;70:30\u20136.","journal-title":"\u010cesk\u00e1 Slovensk\u00e1 Neurologie Neurochirurgie"},{"key":"1566_CR28","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jalz.2014.01.001","volume":"10","author":"F Jessen","year":"2014","unstructured":"Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Ch\u00e9telat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer\u2019s disease. Alzheimers Dement. 2014;10:844\u201352.","journal-title":"Alzheimers Dement"},{"key":"1566_CR29","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:270\u20139.","journal-title":"Alzheimers Dement"},{"key":"1566_CR30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139.","journal-title":"Alzheimers Dement"},{"key":"1566_CR31","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456\u201377.","journal-title":"Brain"},{"key":"1566_CR32","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","volume":"76","author":"ML Gorno-Tempini","year":"2011","unstructured":"Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006\u201314.","journal-title":"Neurology"},{"key":"1566_CR33","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","volume":"256","author":"RC Petersen","year":"2004","unstructured":"Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183\u201394.","journal-title":"J Intern Med"},{"key":"1566_CR34","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1111\/j.1468-1331.2012.03784.x","volume":"19","author":"S Sorbi","year":"2012","unstructured":"Sorbi S, Hort J, Erkinjuntti T, Fladby T, Gainotti G, Gurvit H, et al. EFNS-ENS guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol. 2012;19:1159\u201379.","journal-title":"Eur J Neurol"},{"key":"1566_CR35","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA, American Psychiatric Association, 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"1566_CR36","first-page":"57","volume":"78\/111","author":"H Stepankova","year":"2015","unstructured":"Stepankova H, Nikolai T, Lukavsky J, Bezdicek O, Vrajova M, Kopecek M. Mini\u2013Mental State examination \u2013 Czech normative study. \u010ces Slov Neurol Neurochir. 2015;78\/111:57\u201363.","journal-title":"\u010ces Slov Neurol Neurochir"},{"key":"1566_CR37","doi-asserted-by":"crossref","unstructured":"Nikolai T, Stepankova H, Kopecek M, Sulc Z, Vyhnalek M, Bezdicek O. Normative Data in Older Adults from an International Perspective. J Alzheimers Dis. 2018;61:1233\u201340. The Uniform Data Set, Czech Version:.","DOI":"10.3233\/JAD-170595"},{"key":"1566_CR38","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1093\/arclin\/acs084","volume":"27","author":"O Bezdicek","year":"2012","unstructured":"Bezdicek O, Motak L, Axelrod BN, Preiss M, Nikolai T, Vyhnalek M, et al. Czech version of the trail making test: normative data and clinical utility. Arch Clin Neuropsychol. 2012;27:906\u201314.","journal-title":"Arch Clin Neuropsychol"},{"key":"1566_CR39","first-page":"542","volume":"78","author":"K Drozdova","year":"2015","unstructured":"Drozdova K, Stepankova H, Lukavsky J, Bezdicek O, Kopecek M. Normative data for the rey-osterrieth complex figure test in older Czech adults. Ceska Slov Neurologie Neurochirurgie. 2015;78:542\u20139.","journal-title":"Ceska Slov Neurologie Neurochirurgie"},{"key":"1566_CR40","doi-asserted-by":"crossref","first-page":"307","DOI":"10.14735\/amcsnn2016307","volume":"79\/112","author":"N Zemanova","year":"2016","unstructured":"Zemanova N, Bezdicek O, Michalec J, Nikolai T, Roth J, Jech R, Ruzicka E. Validity study of the Boston naming Test Czech version. Ceska Slov Neurologie Neurochirurgie. 2016;79\/112:307\u201316.","journal-title":"Ceska Slov Neurologie Neurochirurgie"},{"key":"1566_CR41","doi-asserted-by":"publisher","first-page":"292","DOI":"10.14735\/amcsnn2015292","volume":"78","author":"T Nikolai","year":"2015","unstructured":"Nikolai T, \u0160t\u011bp\u00e1nkov\u00e1 H, Michalec J, Bezd\u00ed\u010dek O, Hor\u00e1kov\u00e1 K, Markov\u00e1 H, et al. Testy verb\u00e1ln\u00ed fluence, \u010desk\u00e1 normativn\u00ed studie pro osoby vy\u0161\u0161\u00edho v\u011bku. Ceska Slov Neurologie Neurochirurgie. 2015;78:292\u20139.","journal-title":"Ceska Slov Neurologie Neurochirurgie"},{"key":"1566_CR42","unstructured":"Benton A, Hamsher K. Multilingual aphasia examination. University of Iowa; 1976."},{"key":"1566_CR43","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1177\/1073191116632586","volume":"24","author":"AF Mazancova","year":"2017","unstructured":"Mazancova AF, Nikolai T, Stepankova H, Kopecek M, Bezdicek O. The reliability of clock drawing test Scoring systems modeled on the normative data in healthy aging and nonamnestic mild cognitive impairment. Assessment. 2017;24:945\u201357.","journal-title":"Assessment"},{"key":"1566_CR44","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1515\/cclm-2021-0651","volume":"60","author":"J Gobom","year":"2022","unstructured":"Gobom J, Parnetti L, Rosa-Neto P, Vyhnalek M, Gauthier S, Cataldi S, et al. Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. Clin Chem Lab Med. 2022;60:207\u201319.","journal-title":"Clin Chem Lab Med"},{"key":"1566_CR45","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1159\/000321581","volume":"8","author":"J Lacz\u00f3","year":"2011","unstructured":"Lacz\u00f3 J, Andel R, Vl\u010dek K, Mat\u2019o\u0161ka V, Vyhn\u00e1lek M, Tolar M, et al. Spatial navigation and APOE in amnestic mild cognitive impairment. Neurodegener Dis. 2011;8:169\u201377.","journal-title":"Neurodegener Dis"},{"key":"1566_CR46","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0022-2275(20)43176-1","volume":"31","author":"JE Hixson","year":"1990","unstructured":"Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990;31:545\u20138.","journal-title":"J Lipid Res"},{"key":"1566_CR47","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences. 2 ed. Hillsdale: Lawrence Erlbaum Associates; 1988.","edition":"2"},{"key":"1566_CR48","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4097\/kja.21209","volume":"75","author":"FS Nahm","year":"2022","unstructured":"Nahm FS. Receiver operating characteristic curve: overview and practical use for clinicians. Korean J Anesthesiol. 2022;75:25\u201336.","journal-title":"Korean J Anesthesiol"},{"key":"1566_CR49","first-page":"18","volume":"2","author":"N Bogdanovic","year":"2002","unstructured":"Bogdanovic N, Davidsson P, Gottfries J, Volkman I, Winblad B, Blennow K. Regional and Cellular distribution of synaptic proteins in the normal human brain. Brain Aging. 2002;2:18\u201330.","journal-title":"Brain Aging"},{"key":"1566_CR50","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1002\/hbm.24925","volume":"41","author":"N Falg\u00e0s","year":"2020","unstructured":"Falg\u00e0s N, Ruiz-Peris M, P\u00e9rez-Millan A, Sala-Llonch R, Antonell A, Balasa M, et al. Contribution of CSF biomarkers to early-onset Alzheimer\u2019s disease and frontotemporal dementia neuroimaging signatures. Hum Brain Mapp. 2020;41:2004\u201313.","journal-title":"Hum Brain Mapp"},{"key":"1566_CR51","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1002\/alz.12809","volume":"19","author":"J Nilsson","year":"2023","unstructured":"Nilsson J, Cousins KAQ, Gobom J, Portelius E, Chen-Plotkin A, Shaw LM, et al. Cerebrospinal fluid biomarker panel of synaptic dysfunction in Alzheimer\u2019s disease and other neurodegenerative disorders. Alzheimers Dement. 2023;19:1775\u201384.","journal-title":"Alzheimers Dement"},{"key":"1566_CR52","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jalz.2019.09.001","volume":"16","author":"A Antonell","year":"2020","unstructured":"Antonell A, Tort-Merino A, R\u00edos J, Balasa M, Borrego-\u00c9cija S, Auge JM, et al. Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias. Alzheimers Dement. 2020;16:262\u201372.","journal-title":"Alzheimers Dement"},{"key":"1566_CR53","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jalz.2017.11.015","volume":"14","author":"H Hampel","year":"2018","unstructured":"Hampel H, Toschi N, Baldacci F, Zetterberg H, Blennow K, Kilimann I, et al. Alzheimer\u2019s disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: A\u03b21\u201342, total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40. Alzheimers Dement. 2018;14:492\u2013501.","journal-title":"Alzheimers Dement"},{"key":"1566_CR54","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.3233\/JAD-170368","volume":"59","author":"S Lista","year":"2017","unstructured":"Lista S, Toschi N, Baldacci F, Zetterberg H, Blennow K, Kilimann I, et al. Cerebrospinal fluid neurogranin as a biomarker of neurodegenerative diseases: a cross-sectional study. J Alzheimers Dis. 2017;59:1327\u201334.","journal-title":"J Alzheimers Dis"},{"key":"1566_CR55","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s40520-019-01326-z","volume":"32","author":"IA Mavroudis","year":"2020","unstructured":"Mavroudis IA, Petridis F, Chatzikonstantinou S, Kazis D. A meta-analysis on CSF neurogranin levels for the diagnosis of Alzheimer\u2019s disease and mild cognitive impairment. Aging Clin Exp Res. 2020;32:1639\u201346.","journal-title":"Aging Clin Exp Res"},{"key":"1566_CR56","doi-asserted-by":"publisher","first-page":"e12258","DOI":"10.1002\/dad2.12258","volume":"14","author":"U Morar","year":"2022","unstructured":"Morar U, Izquierdo W, Martin H, Forouzannezhad P, Zarafshan E, Unger E, et al. A study of the longitudinal changes in multiple cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers on converter and non-converter Alzheimer\u2019s disease subjects with consideration for their amyloid beta status. Alzheimers Dement (Amst). 2022;14:e12258.","journal-title":"Alzheimers Dement (Amst)"},{"key":"1566_CR57","doi-asserted-by":"crossref","unstructured":"Dulewicz M, Kulczy\u0144ska-Przybik A, Borawska R, S\u0142owik A, Mroczko B. Evaluation of synaptic and axonal dysfunction biomarkers in Alzheimer\u2019s disease and mild cognitive impairment based on CSF and Bioinformatic Analysis. Int J Mol Sci. 2022;23.","DOI":"10.3390\/ijms231810867"},{"key":"1566_CR58","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41398-020-0801-2","volume":"10","author":"W Liu","year":"2020","unstructured":"Liu W, Lin H, He X, Chen L, Dai Y, Jia W, et al. Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer\u2019s disease and mild cognitive impairment. Transl Psychiatry. 2020;10:125.","journal-title":"Transl Psychiatry"},{"key":"1566_CR59","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1080\/00207454.2021.1881087","volume":"132","author":"Z Wang","year":"2022","unstructured":"Wang Z, Yang J, Zhu W, Tang Y, Jia J. The synaptic marker neurogranin as a disease state biomarker in Alzheimer\u2019s disease: a systematic review and meta-analysis. Int J Neurosci. 2022;132:1245\u201353.","journal-title":"Int J Neurosci"},{"key":"1566_CR60","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1111\/ene.14658","volume":"28","author":"I \u00c1lvarez","year":"2021","unstructured":"\u00c1lvarez I, Diez-Fairen M, Aguilar M, Gonz\u00e1lez JM, Ysamat M, Tartari JP, et al. Added value of cerebrospinal fluid multimarker analysis in diagnosis and progression of dementia. Eur J Neurol. 2021;28:1142\u201352.","journal-title":"Eur J Neurol"},{"key":"1566_CR61","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13195-015-0161-y","volume":"7","author":"K Hellwig","year":"2015","unstructured":"Hellwig K, Kvartsberg H, Portelius E, Andreasson U, Oberstein TJ, Lewczuk P, et al. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer\u2019s disease. Alzheimers Res Ther. 2015;7:74.","journal-title":"Alzheimers Res Ther"},{"key":"1566_CR62","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.jalz.2015.05.012","volume":"11","author":"A De Vos","year":"2015","unstructured":"De Vos A, Jacobs D, Struyfs H, Fransen E, Andersson K, Portelius E, et al. C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer\u2019s disease. Alzheimers Dement. 2015;11:1461\u20139.","journal-title":"Alzheimers Dement"},{"key":"1566_CR63","doi-asserted-by":"publisher","first-page":"9365","DOI":"10.18632\/aging.103211","volume":"12","author":"M Xue","year":"2020","unstructured":"Xue M, Sun F-R, Ou Y-N, Shen X-N, Li H-Q, Huang Y-Y, et al. Association of cerebrospinal fluid neurogranin levels with cognition and neurodegeneration in Alzheimer\u2019s disease. Aging. 2020;12:9365\u201379.","journal-title":"Aging"},{"key":"1566_CR64","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jamaneurol.2016.0086","volume":"73","author":"R Tarawneh","year":"2016","unstructured":"Tarawneh R, D\u2019Angelo G, Crimmins D, Herries E, Griest T, Fagan AM, et al. Diagnostic and Prognostic Utility of the synaptic marker neurogranin in Alzheimer Disease. JAMA Neurol. 2016;73:561\u201371.","journal-title":"JAMA Neurol"},{"key":"1566_CR65","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1093\/brain\/awv267","volume":"138","author":"E Portelius","year":"2015","unstructured":"Portelius E, Zetterberg H, Skillb\u00e4ck T, T\u00f6rnqvist U, Andreasson U, Trojanowski JQ, et al. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer\u2019s disease. Brain. 2015;138:3373\u201385.","journal-title":"Brain"},{"key":"1566_CR66","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13195-023-01212-x","volume":"15","author":"S Das","year":"2023","unstructured":"Das S, Goossens J, Jacobs D, Dewit N, Pijnenburg YAL, I\u2019tV SGJG, et al. Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer\u2019s disease and frontotemporal dementia. Alzheimers Res Ther. 2023;15:62.","journal-title":"Alzheimers Res Ther"},{"key":"1566_CR67","doi-asserted-by":"publisher","first-page":"11135","DOI":"10.1038\/srep11135","volume":"5","author":"A Petersen","year":"2015","unstructured":"Petersen A, Gerges NZ. Neurogranin regulates CaM dynamics at dendritic spines. Sci Rep. 2015;5:11135.","journal-title":"Sci Rep"},{"key":"1566_CR68","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3233\/JAD-220452","volume":"91","author":"MA R\u00e5destig","year":"2023","unstructured":"R\u00e5destig MA, Skoog J, Zetterberg H, Skillb\u00e4ck T, Zettergren A, Sterner TR, et al. Subtle differences in Cognition in 70-Year-Olds with elevated cerebrospinal fluid neurofilament light and neurogranin: a H70 cross-sectional study. J Alzheimers Dis. 2023;91:291\u2013303.","journal-title":"J Alzheimers Dis"},{"key":"1566_CR69","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","volume":"9","author":"C-C Liu","year":"2013","unstructured":"Liu C-C, Liu C-C, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9:106\u201318.","journal-title":"Nat Rev Neurol"},{"key":"1566_CR70","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.jalz.2016.05.003","volume":"12","author":"X Sun","year":"2016","unstructured":"Sun X, Dong C, Levin B, Crocco E, Loewenstein D, Zetterberg H, et al. APOE \u03b54 carriers may undergo synaptic damage conferring risk of Alzheimer\u2019s disease. Alzheimers Dement. 2016;12:1159\u201366.","journal-title":"Alzheimers Dement"},{"key":"1566_CR71","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jalz.2019.01.004","volume":"15","author":"I Bos","year":"2019","unstructured":"Bos I, Vos S, Verhey F, Scheltens P, Teunissen C, Engelborghs S, et al. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer\u2019s disease spectrum. Alzheimers Dement. 2019;15:644\u201354.","journal-title":"Alzheimers Dement"},{"key":"1566_CR72","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/14737175.2016.1204234","volume":"17","author":"S Lista","year":"2017","unstructured":"Lista S, Hampel H. Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer\u2019s disease. Expert Rev Neurother. 2017;17:47\u201357.","journal-title":"Expert Rev Neurother"},{"key":"1566_CR73","doi-asserted-by":"publisher","first-page":"117727192095031","DOI":"10.1177\/1177271920950319","volume":"15","author":"E Camporesi","year":"2020","unstructured":"Camporesi E, Nilsson J, Brinkmalm A, Becker B, Ashton NJ, Blennow K, et al. Fluid biomarkers for synaptic dysfunction and loss. Biomark Insights. 2020;15:1177271920950319.","journal-title":"Biomark Insights"},{"key":"1566_CR74","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaneurol.2015.3037","volume":"73","author":"H Zetterberg","year":"2016","unstructured":"Zetterberg H, Skillb\u00e4ck T, Mattsson N, Trojanowski JQ, Portelius E, Shaw LM, et al. Association of Cerebrospinal Fluid Neurofilament Light Concentration with Alzheimer Disease Progression. JAMA Neurol. 2016;73:60.","journal-title":"JAMA Neurol"},{"key":"1566_CR75","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.3390\/cells12091309","volume":"12","author":"KY Kim","year":"2023","unstructured":"Kim KY, Shin KY, Chang K-A. GFAP as a potential biomarker for Alzheimer\u2019s Disease: a systematic review and Meta-analysis. Cells. 2023;12:1309.","journal-title":"Cells"},{"key":"1566_CR76","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.neurobiolaging.2022.03.019","volume":"117","author":"F Massa","year":"2022","unstructured":"Massa F, Halbgebauer S, Barba L, Oeckl P, G\u00f3mez de San Jos\u00e9 N, Bauckneht M, et al. Exploring the brain metabolic correlates of process-specific CSF biomarkers in patients with MCI due to Alzheimer\u2019s disease: preliminary data. Neurobiol Aging. 2022;117:212\u201321.","journal-title":"Neurobiol Aging"},{"key":"1566_CR77","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","volume":"90","author":"L Gaetani","year":"2019","unstructured":"Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90:870\u201381.","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01566-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-024-01566-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01566-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T08:12:01Z","timestamp":1725610321000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-024-01566-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,6]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1566"],"URL":"https:\/\/doi.org\/10.1186\/s13195-024-01566-w","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,6]]},"assertion":[{"value":"5 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants included in the study signed an informed consent approved by the Motol University Hospital ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"199"}}